Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
11040 Roselle Street , San Diego, CA, 92121, US
If you are considering an LNP-based formulation or another complex drug, here are several points to consider to make the process more efficient.
Released By Ajinomoto Bio-Pharma Services
As a member of the Ajinomoto Group, we offer an extensive global reach with facilities in Belgium, United States, Japan, and India.
To ensure safety during HPAPI production, manufacturers must have the knowledge to effectively use containment and design high-quality equipment.
How can you maintain a manageable budget while procuring a high-quality plasmid supply?
The push to reduce carbon emissions across some of the most energy-intensive industries has created new complexities for many companies.
After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene.
A clear increase in continuous flow processes has emerged over the past decade.
Below are five key areas where pharmaceutical manufacturers may face the biggest uphill battles.
The rise of biologics is having a dramatic impact on how physicians treat many serious and chronic illnesses.
The bulk drug substance, formulation, and sterile filtering and filling of the final drug product all require special handling procedures.
Often, the implementation of specialized equipment and/or processes is necessary to ensure successful formulation.
Finding the CDMO that is right for your company and project can be a daunting task, particularly if this is your first time outsourcing.
San Diego, October 4, 2016 – Ajinomoto Althea, Inc. (“Althea”) announced that a biologics candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using CORYNEX® Protein Expression System, has entered phase I clinical trials. The CORYNEX® system of Ajinomoto Co., Inc. (“Ajinomoto Co.”) is a proprietary protein expression platform that combines […]
SAN DIEGO, CA, May 17, 2016 — Ajinomoto Althea Inc., a leading provider of biotherapeutic contract development and manufacturing services, today announced that the United States Patent and Trademark Office has issued US Patent 9,310,379 covering methods to crystallize monoclonal antibodies for the purpose of scale up and cGMP manufacturing for therapeutic use. The patented […]
SAN DIEGO – December 10th, 2015 — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs). The new facility is located in close proximity to existing Althea […]
SAN DIEGO – March 15, 2016 — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biologics contract development and manufacturing services, announced today it is expanding the capacity of its Fill and Finish operations through the addition of a second manufacturing shift. Althea’s contract manufacturing business has experienced exceptionally strong growth driven by biotech companies […]
Last week, Ajinomoto Althea, Inc. (“Althea”) was awarded the California Competes Tax Credit by the California Governor’s Office of Business and Economic Development (“GO-Biz”). The $2,000,000 income tax credit was granted because of Althea’s continued commitment to grow and invest in its California-based operations. The Althea award was the largest granted to a San Diego […]
SAN DIEGO – [6.16.15] — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority (HPRA) for commercial aseptic filling and testing. The HPRA conducted a five day on-site inspection which commenced on February […]
SAN DIEGO – March 31, 2015 — Ajinomoto Althea, Inc. (“Althea”), a leading provider of biopharmaceutical contract development and manufacturing services, announced today that it has added two more top pharmaceutical companies to its growing list of partners in developing and manufacturing cGMP-produced crystal based drug products using Althea’s Crystalomics® drug delivery technology. With these […]
Why pharma needs automated AI security now.
By: Frank Balonis
Welcomes Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.
By: Charlie Sternberg
Dr. Abdul Mutlib is appointed the President of Frontage Laboratories, Canada, and will spearhead growth as he continues to serve as Chief Scientific & Strategy Officer.
By: Rachel Klemovitch
Strengthens BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701.
Forms a rare tumor business for Merck KGaA, Darmstadt, Germany, including SpringWorks’ portfolio and pimicotinib.
The U.S. launch of Conexxence and Bomyntra follows the FDA’s approval in March 2025.
Richard Thakor and Daniel Anderson will speak at the event in November.
Strengthens its global particle engineering capabilities.
Will manufacture SurVaxM, a novel immunotherapeutic vaccine designed to treat glioblastoma, for use in clinical trials.
Integrate Keystone’s Key-Pak child-resistant blister cards with Med-Con’s medication adherence prompting and monitoring application.
The company is investing $90 million to expand two U.S. facilities to enhance capacity and efficiency.
Villain offers extensive expertise in peptide and oligonucleotide development and manufacturing.
Collaboration aims to discover and develop novel therapeutics for cardiovascular disease using Novartis’ ProFoundry Platform.
It is the only ready-to-use liquid immunoglobulin therapy with (IgA) content and is set for commercialization in 2026.
The companies have released the first batch of Novalgen’s next-generation T-cell engager for first in-human clinical trials.
The collaboration now is progressing to the in vivo preclinical stage.
Will further expand its domestic capabilities to develop, produce and deliver medicines.
EVP & COO Todd Nelson reflects on Porton J-STAR's defining milestones, global network strategy, and what’s ahead as the company enters its third decade.
Released By Porton
The clinical site is expected to be completed and ready for media fill by the end of 2029.
The company’s label updates are for its CAR T cell therapies, Breyanzi and Abecma.
Is purpose-built for manufacturing high-quality plasmid DNA and viral vectors.
Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions.
Hervé Hoppenot will retire after 11 years of leading the company through major expansion.
Will commence cell therapy process development and clinical manufacturing services at AGC Inc.’s Yokohama Technical Center.
Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer treatments.
Will develop and commercialize a potential treatment for obesity and metabolic disease based on technology licensed from the U.S. Department of Veterans Affairs.
Addressing increasing complexity, cost of drug development, and navigating regulatory compliance.
By: Kristin Brooks
Will add further sterile fill/finish capacity over the course of the next year.
Agnus joins Bora Group from KBI Biopharma, where he led global business development.
ST16 Semi-Automated Aggregation Station combines software and flexible hardware to help optimize productivity, improve operational efficiency and streamline processes.
J.D. Mowery brings nearly 25 years of experience in the CDMO and biopharmaceutical industries.
Will combine their biomanufacturing facilities to create a global service for biologics development and supply.
The newly acquired facility provides drug product manufacturing services for sterile injectables.
This strategic partnership provides end-to-end visibility and best-in-class track and trace for Praxis’s customer base.
This integrated solution follows the company’s acquisition of Pharmacontrol Electronic and combines technologies.
This acquisition enhances Systech’s product offerings and enables it to offer a more comprehensive product portfolio to its customers.
Offers quick compliance, avoids delays, and optimizes production with multi-scan and mobile flexibility.
Jeff Speicher of PLD Pharma Services on market shifts, customer trends, and the complexities of onboarding at CPHI Americas 2025.
Released By PLD Pharma Services
The CDMO's head of development talks about ADCs, accelerated timelines, and the push for end-to-end development services.
By: Tim Wright
This project could reduce costs in pharmaceutical development and manufacturing.
The new bioconjugation site completes the CDMO’s capabilities across payload, linker, and Mab, with onboarding set to start in September.
Partnership aims to advance Fractyl Health’s Rejuva pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes.
Will invest $90 million towards expanding its facilities in Lexington, Kentucky and Riverview, Michigan.
From serialization and sustainability to patient-centric design, experts reveal the trends shaping the contract packaging outsourcing market.
For this roundtable, Contract Pharma called upon thought leaders across the pharmaceutical services sector to address “3 Key Trends” impacting the CDMO industry in 2025 and beyond.
Enhances its capabilities in U.S. drug product manufacturing for aseptic filling of prefilled syringes & cartridges.
Hasagic brings 20+ years of experience in the healthcare, life science, and specialty chemicals industries.
Will unite RoosterBio’s portfolio of hMSC-based products and processes with Thermo Fisher’s advanced therapy GMP contract manufacturing capabilities.
Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decrease lead time to Investigational New Drug (IND).
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
